Skip to main content
Altuviiio logo

ALTUVIIIO® Patient Experiences 


Beyond the Clinic: A Shared Approach to Treatment Decisions

Watch Dr Janbain and Eli spend the day together as they share his experience of switching to ALTUVIIIO.

VOICE OVER

VO (background): Eli, go for it

Eli (to camera): Hi, I’m Eli, I’m 21 years old, and I have hemophilia A.

Dr. Janbain: Hi, I’m Maissaa Janbain, I’m a hematologist and I have been taking care of Eli for over 12 years.

Dr. Janbain: What are you going to do today? I’m so excited.

Eli: We’re gonna to play some soccer.

Dr. Janbain: Finally, I’ll get to see you playing it in person!

Eli: I can show you some of my skills.

Eli: We’re gonna play some soccer, gonna talk about ALTUVIIIO, and we’re just gonna have a really great day in the city of New Orleans

Dr. Janbain: Seeing him outside of the clinic setting, not just listening to what I’m saying, but showing me how you live your life, that's gonna be so exciting.

Dr. Janbain (to camera): Cut!

Eli (playfully): Cut.

Eli: I was first diagnosed with hemophilia at 6 months old.

Eli: There were a few things growing up that I couldn’t do, like play football, and like, roughhouse, but I was able to do some of the less contact sports like soccer.

Eli: I started playing soccer around 3 or 4 years old. I love the sport, I love watching it.       
Like, it brings you together with people. And even when you’re not with people, you can go out there by yourself and kick the ball around. And the ball will be your best friend.

Dr. Janbain: I definitely remember the first time I met him, it was all about soccer.

Eli: My doctors and my healthcare team have always been there for me, wanting the best for me, they’ve always just wanted to see me grow up like a normal kid. I trust her advice and what she has to say. She helps me out and makes sure that I’m living the everyday dream life of hemophilia A.

Eli: I’m a teach you how to score a goal.

Dr. Janbain (laughing): Oh great. I think it depends on the keeper too.

Eli: When I first sat down and talked about my treatment goals and making that switch to ALTUVIIIO, the things that mattered most to me were, am I going to be happy? And am I still going to be able to do the things that I want to do every single day? And is there anything that’s going to hold me back? I needed a treatment that kept me protected during daily life, every single day.

Dr. Janbain: I didn’t want him to hold from being active, but I just wanted him to be active in a way that does not increase his bleeding risk.

Dr. Janbain: The number one priority for me is to protect them.

All (in mixed unison): One, two, three. Team!

Eli: At first I didn’t want to switch. It was really just a comfort thing. I was comfortable and didn’t want to be uncomfortable. And then I was asked about ALTUVIIIO. And I really started looking into it. And I started asking myself, ‘Is the medicine I’m taking right now really fit for my day-to-day lifestyle?’ And the answer was no. So I finally made the decision to switch over to ALTUVIIIO.

Dr. Janbain: With my patients, and specifically patients like Eli, I do discuss the importance of Factor VIII levels.

Dr. Janbain: I told Eli that ALTUVIIIO keeps Factor VIII levels above 40% for most of the week in adults.

Eli: Growing up, I just thought I was taking medicine just to make me normal. I didn’t really understand how much my levels actually fluctuate.

Eli: After having talks about ALTUVIIIO and what it would do for me and how it would keep my levels higher for longer, I wanted to make the switch right away.

Eli (to crew): Wait, could I look at that one more time?

Eli: Dr. Janbain made sure I understood the common side effects, which include headaches and joint pain.

Eli: The sunniest, most poppin’ spot in town…

Eli: ALTUVIIIO for me, it’s been great day to day.

Eli: I feel like I can do anything that I would normally want to do throughout the day.

Eli: With ALTUVIIIO, I infuse once a week. I have had 1 or 2 breakthrough bleeds and I have had to use an on-demand emergency dose for those, but that’s only happened once or twice.

Dr. Janbain: Hearing that Eli is doing great and ALTUVIIIO is providing him protection without adding burden of treatment to his life is definitely rewarding as a provider.

Dr. Janbain (to Eli): Is there something you wish more doctors knew or considered when it comes to treating young people with hemophilia?

Eli: Patients wanna do what they wanna do, and like what they enjoy, and what they love. I feel like, we’ve had conversations, and more trust of, like, how I can go kick the soccer ball around with my friends and you don’t have to worry so much.

Eli: It’s definitely better to speak up and tell your doctors what’s on your mind and what you wanna do.

Dr. Janbain: I always want them to understand that the more they share with me, the more the treatment plan we develop will be fit for them.

Eli: I just wish all doctors would give their patients the chance to just try to live as normal as possible.

Eli: Switching can be hard, but for me it was definitely worth it.

Eli: This has been my experience with ALTUVIIIO, but everyone’s experience is different     

 Dr. Janbain (in background, fading out): We did it!

Eli: I’m being compensated by Sanofi to share my story.

Dr. Janbain: I am being compensated by Sanofi to share my experience.    


 

Explore more stories of patients who made the switch to ALTUVIIIO

Which patients do you typically see in your practice?

Male adult patients discuss what drove them to make a change

Brad

“I was constantly having bleeds when I was active.”

Chris

"I’ve tried 7 different treatments over my lifetime.”

Daniel

“I was managing my hemophilia, but that was before college.”

Derek

“ALTUVIIIO helped my daughter Brooklynn. I thought it would work for me.”

DJ

“I wanted less time infusing and more time with my son.”

Mickey

“I really wanted fewer infusions.”

Tommy

"As an outdoorsman, my joint health is especially important to me.”

Pediatric and adolescent patients and their caregivers discuss evolving needs

Allison and Emilio

"With his schedule, it’s important for us to be confident in his bleed protection.”

Ashley and Harrison

“My son was still having to get factor while on subcutaneous prophylaxis.”

Nika and Zander

“Since ALTUVIIIO, he hasn’t been constantly infusing.”

 

Jenny and Paxton

“Paxton was experiencing more breakthrough bleeding with his old treatment.” 

Female patients discuss their unique treatment journeys

Brooklynn

“I needed a medicine with bleed protection.”

Chrissy

"My prophylaxis regimen wasn’t working for me.”

Courtney

“Before ALTUVIIIO, I kept having breakthrough bleeding.”

Morgan

"I had a health scare that required surgery, so I sought a factor replacement therapy."

Indication

ALTUVIIIO® is indicated for use in adults and pediatric patients with hemophilia A (congenital factor VIII deficiency) for:

  • Routine prophylaxis to reduce the frequency of bleeding episodes
  • On-demand treatment and control of bleeding episodes
  • Perioperative management of bleeding
Limitation of Use

ALTUVIIIO is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Contraindications

ALTUVIIIO is contraindicated in patients who have had severe hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

Warnings and Precautions
  • Allergic-type hypersensitivity reactions, including anaphylaxis, have occurred with ALTUVIIIO. Discontinue use of ALTUVIIIO if hypersensitivity reaction occurs and manage symptoms as appropriate.
  • Formation of neutralizing antibodies (inhibitors) to Factor VIII has been reported following administration of ALTUVIIIO. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests.
  • If assessment of plasma Factor VIII activity is needed, it is recommended to use a validated one-stage clotting assay. The ALTUVIIIO Factor VIII activity level is overestimated by the chromogenic assay and a specific ellagic acid-based aPTT reagent in one-stage clotting assay by approximately 2.5-fold. If these assays are used, divide the result by 2.5 to approximate the patient's ALTUVIIIO Factor VIII activity level.
Adverse Reactions

The most common adverse reactions (>10% of subjects) reported in clinical trials were headache and arthralgia.

Indication

Important Safety Information

© 2026 Sanofi. All rights reserved. All trademarks mentioned are the property of the Sanofi group. MAT-US-2508205-v3.0-08/2026 Last Updated: August 2026